

Resource Summary Report

Generated by NIF on Jul 31, 2026

CD107a (LAMP-1)

RRID:AB_2738458

Type: Antibody

Proper Citation

BD Biosciences Cat# 563869, RRID:AB_2738458

Antibody Information

URL: http://antibodyregistry.org/AB_2738458

Proper Citation: BD Biosciences Cat# 563869, RRID:AB_2738458

Target Antigen: CD107a (LAMP-1)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Intracellular staining (flow cytometry)

Antibody Name: CD107a (LAMP-1)

Description: This monoclonal targets CD107a (LAMP-1)

Target Organism: human

Clone ID: H4A3

Antibody ID: AB_2738458

Vendor: BD Biosciences

Catalog Number: 563869

Record Creation Time: 20250819T221911+0000

Record Last Update: 20250820T014841+0000

Ratings and Alerts

No rating or validation information has been found for CD107a (LAMP-1).

No alerts have been found for CD107a (LAMP-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Stampfer SD, et al. (2025) Mpox-specific cellular and humoral immunity in mpox survivors living with HIV. *Cell reports*, 44(11), 116501.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ 2a. *Cell*, 187(5), 1238.

Delconte RB, et al. (2024) Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. *Immunity*, 57(8), 1923.

Nicolas A, et al. (2023) An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. *iScience*, 26(1), 105904.

Dubé M, et al. (2023) Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. *Cell host & microbe*, 31(9), 1507.

Sannier G, et al. (2023) A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. *Cell reports. Medicine*, 4(3), 100955.

Xue J, et al. (2022) Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. *Cell*, 185(1), 131.

Sun Y, et al. (2022) Protocol for evaluating CD8+ T cell-mediated immunity in latently SHIV-infected rhesus macaques with HIV fusion-inhibitory lipopeptide monotherapy. *STAR protocols*, 3(3), 101479.

Nayrac M, et al. (2022) Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. *Cell reports*, 39(13), 111013.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Tauzin A, et al. (2021) A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell host & microbe*, 29(7), 1137.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Cell, 183(2), 347.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell reports. Medicine, 1(8), 100141.